Sorafenib 200mg Tab
| Product Overview | |
| Generic Name | Sorafenib 200mg Tab |
| Brand Name(s) | Nexavar |
| Form | Oral film-coated tablets |
| Strength | 200 mg |
| Therapeutic Class | Multikinase inhibitor (VEGFR/RAF/PDGFR) antineoplastic agent |
| ATC Code | L01EX02 |
| Manufacturing & Regulatory | |
| Manufacturer | Bayer |
| Country | India/USA/EU |
| GMP Compliance | FDA/EMA/WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | Batch-specific |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 24 months |
| Storage | 20-25 °C (15-30 °C allowed) |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request, not publicly posted |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
Indications & Use: - Hepatocellular Carcinoma (HCC): First-line treatment for unresectable HCC in adult patients. - Renal Cell Carcinoma (RCC): Advanced RCC after failure of prior interferon-alpha or IL-2-based therapy. - Differentiated Thyroid Carcinoma (DTC): Locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC (papillary, follicular, or Hürthle cell carcinoma)
